LINCOLN.NS Stock Analysis
LI
Avoid
Based on Eyestock quantitative analysis, LINCOLN.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.034
Dividend yield
0.29 %
Shares outstanding
20.03 B
Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat and currently employs 1,700 full-time employees. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.